The role of cytokines in cancer cachexia

A large number of observations point towards cytokines, polypeptides released mainly by immune cells, as the molecules responsible for the metabolic derangements associated with cancer‐bearing states. Indeed, these alterations lead to a pathological state known as cancer cachexia which is, unfortunately, one of the worst effects of malignancy, accounting for nearly a third of cancer deaths. It is characterized by weight loss together with anorexia, weakness, anemia, and asthenia. The complications associated with the appearance of the cachectic syndrome affect both the physiological and biochemical balance of the patient and have effects on the efficiency of the anticancer treatment, resulting in a considerably decreased survival time. At the metabolic level, cachexia is associated with loss of skeletal muscle protein together with a depletion of body lipid stores. The cachectic patient, in addition to having practically no adipose tissue, is basically subject to an important muscle wastage manifested as an excessive nitrogen loss. The metabolic changes are partially mediated by alterations in circulating hormone concentrations (insulin, glucagon, and glucocorticoids in particular) or in their effectiveness. The present study reviews the involvement of different cytokines in the metabolic and physiological alterations associated with tumor burden and cachexia. Among these cytokines, some can be considered as procachectic (such as tumor necrosis factor‐α), while others having opposite effects can be named as anticachectic cytokines. It is the balance between these two cytokine types that finally seems to have a key role in cancer cachexia. © 1999 John Wiley & Sons, Inc. Med Res Rev, 19, No. 3, 223–248, 1999.

[1]  B. Barton,et al.  Cancer cachexia is mediated in part by the induction of IL-6-like cytokines from the spleen. , 2001, Cytokine.

[2]  Jiandie D. Lin,et al.  Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. , 2001, Molecular cell.

[3]  M. Tisdale,et al.  Cachexia in MAC16 adenocarcinoma: suppression of hunger despite normal regulation of leptin, insulin and hypothalamic neuropeptide Y , 2001, Journal of neurochemistry.

[4]  A. Liu,et al.  [Cytokines in experimental cancer cachexia]. , 2001, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[5]  A. Więcek,et al.  [Plasma concentration of leptin, neuropeptide Y and tumor necrosis factor alpha in patients with cancers, before and after radio- and chemotherapy]. , 2001, Polskie Archiwum Medycyny Wewnetrznej.

[6]  P. Ghezzi,et al.  Role of cytokines in cancer cachexia in a murine model of intracerebral injection of human tumours. , 2001, Cytokine.

[7]  V. Almendro,et al.  Curcumin, a natural product present in turmeric, decreases tumor growth but does not behave as an anticachectic compound in a rat model. , 2001, Cancer letters.

[8]  M. Piras,et al.  Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites , 2001, Journal of Molecular Medicine.

[9]  T. Ogihara,et al.  Intravenous injection of oligodeoxynucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice , 2001, Gene Therapy.

[10]  R. Bellantone,et al.  Increased muscle ubiquitin mRNA levels in gastric cancer patients. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[11]  J. Belizário,et al.  Cleavage of caspases-1, -3, -6, -8 and -9 substrates by proteases in skeletal muscles from mice undergoing cancer cachexia , 2001, British Journal of Cancer.

[12]  J. Fischer,et al.  The transcription factors NF-kappab and AP-1 are differentially regulated in skeletal muscle during sepsis. , 2001, Biochemical and biophysical research communications.

[13]  M. Breslow,et al.  Weight loss is not associated with hyperleptinemia in humans with pancreatic cancer. , 2001, The Journal of clinical endocrinology and metabolism.

[14]  G. Mantovani,et al.  Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites , 2000, Journal of Molecular Medicine.

[15]  C. Plata-salamán Central nervous system mechanisms contributing to the cachexia-anorexia syndrome. , 2000, Nutrition.

[16]  V. Baracos Regulation of skeletal-muscle-protein turnover in cancer-associated cachexia. , 2000, Nutrition.

[17]  K. Lundholm,et al.  Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. , 2000, Cancer research.

[18]  C. Y. Wang,et al.  NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. , 2000, Science.

[19]  R. Dunlop,et al.  Cytokines and advanced cancer. , 2000, Journal of pain and symptom management.

[20]  F. López‐Soriano,et al.  Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats , 2000, British Journal of Cancer.

[21]  F. López‐Soriano,et al.  DNA fragmentation occurs in skeletal muscle during tumor growth: A link with cancer cachexia? , 2000, Biochemical and biophysical research communications.

[22]  L. Tessitore,et al.  Leptin expression in colorectal and breast cancer patients. , 2000, International journal of molecular medicine.

[23]  B. Barton,et al.  A model that reproduces syndromes associated with human multiple myeloma in nonirradiated SCID mice. , 2000, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[24]  P. Widdowson,et al.  Effect of cytokines on hypothalamic neuropeptide Y release in vitro , 2000, Peptides.

[25]  K. Fearon,et al.  Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor , 2000, The British journal of surgery.

[26]  N. Forsberg,et al.  Effects of ciliary neurotrophic factor (CNTF) on protein turnover in cultured muscle cells. , 2000, Cytokine.

[27]  E. Bruera,et al.  Potential novel uses of thalidomide: focus on palliative care. , 2000, Drugs.

[28]  M. Tisdale,et al.  Effect of a cancer cachectic factor on protein synthesis/degradation in murine C2C12 myoblasts: modulation by eicosapentaenoic acid. , 1999, Cancer research.

[29]  L. Tessitore,et al.  Leptin and tumor growth in rats , 1999, International journal of cancer.

[30]  M. Tisdale,et al.  Catabolism of adipose tissue by a tumour‐produced lipid‐mobilising factor , 1999, International journal of cancer.

[31]  O. Ishiko,et al.  Lipolytic activity of anemia-inducing substance from tumor-bearing rabbits. , 1999, Nutrition and cancer.

[32]  T. Ogihara,et al.  Intratumoral injection of oligonucleotides to the NFκB binding site inhibits cachexia in a mouse tumor model , 1999, Gene Therapy.

[33]  F. López‐Soriano,et al.  In the rat, tumor necrosis factor α administration results in an increase in both UCP2 and UCP3 mRNAs in skeletal muscle: a possible mechanism for cytokine‐induced thermogenesis? , 1998, FEBS letters.

[34]  N. Agell,et al.  Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. , 1998, Cancer letters.

[35]  F. López‐Soriano,et al.  Skeletal muscle UCP2 and UCP3 gene expression in a rat cancer cachexia model , 1998, FEBS letters.

[36]  M. Tisdale,et al.  Mechanism of muscle protein degradation induced by a cancer cachectic factor. , 1998, British Journal of Cancer.

[37]  R. Schwartz,et al.  Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-κB activation in response to tumor necrosis factor α , 1998 .

[38]  M. Tisdale,et al.  Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. , 1998, Cancer research.

[39]  F. López‐Soriano,et al.  Catabolic proinflammatory cytokines. , 1998, Current opinion in clinical nutrition and metabolic care.

[40]  R. Surwit,et al.  Diet-induced changes in uncoupling proteins in obesity-prone and obesity-resistant strains of mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R. Faggioni,et al.  Induction of UCP2 gene expression by LPS: a potential mechanism for increased thermogenesis during infection. , 1998, Biochemical and biophysical research communications.

[42]  D. McMillan,et al.  Albumin synthesis rates are not decreased in hypoalbuminemic cachectic cancer patients with an ongoing acute-phase protein response. , 1998, Annals of surgery.

[43]  P. Bijlenga,et al.  Uncoupling Protein-3 Expression in Rodent Skeletal Muscle Is Modulated by Food Intake but Not by Changes in Environmental Temperature* , 1998, The Journal of Biological Chemistry.

[44]  R. Schwartz,et al.  Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[45]  O. Ishiko,et al.  Mechanism of depletion of liver glycogen in cancer cachexia. , 1997, Biochemical and biophysical research communications.

[46]  K. Nakao,et al.  Cloning of rat uncoupling protein‐3 and uncoupling protein‐2 cDNAs: their gene expression in rats fed high‐fat diet , 1997, FEBS letters.

[47]  B. Lowell,et al.  The Human Uncoupling Protein-3 Gene , 1997, The Journal of Biological Chemistry.

[48]  M. Tisdale,et al.  Induction of muscle protein degradation by a tumour factor. , 1997, British Journal of Cancer.

[49]  F. López‐Soriano,et al.  The metabolic basis of cancer cachexia , 1997, Medicinal research reviews.

[50]  O. Boss,et al.  Tissue‐dependent upregulation of rat uncoupling protein‐2 expression in response to fasting or cold , 1997, FEBS letters.

[51]  B. Lowell,et al.  UCP3: an uncoupling protein homologue expressed preferentially and abundantly in skeletal muscle and brown adipose tissue. , 1997, Biochemical and biophysical research communications.

[52]  O. Boss,et al.  Uncoupling protein‐3: a new member of the mitochondrial carrier family with tissue‐specific expression , 1997, FEBS letters.

[53]  L. Tartaglia,et al.  Cloning and Characterization of an Uncoupling Protein Homolog: A Potential Molecular Mediator of Human Thermogenesis , 1997, Diabetes.

[54]  H. Moshage Cytokines and the hepatic acute phase response , 1997, The Journal of pathology.

[55]  N. Rothwell,et al.  Involvement of cytokines in cachexia induced by T-cell leukaemia in the rat. , 1997, European cytokine network.

[56]  Christophe Fleury,et al.  Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia , 1997, Nature Genetics.

[57]  V. Praloran,et al.  Concentrations of serum leukemia inhibitory factor (LIF) in patients with hematologic malignances , 1997, Leukemia.

[58]  N. Agell,et al.  TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscles. , 1997, Biochemical and biophysical research communications.

[59]  Dennis J. Rivet,et al.  Multiple Cytokines and Acute Inflammation Raise Mouse Leptin Levels: Potential Role in Inflammatory Anorexia , 1997, The Journal of experimental medicine.

[60]  E. Wouters,et al.  Plasma concentration of total leptin and human lung-cancer-associated cachexia. , 1997, Clinical science.

[61]  A. De Luca,et al.  Electrical properties of diaphragm and EDL muscles during the life of dystrophic mice. , 1997, The American journal of physiology.

[62]  C. Plata-salamán,et al.  Neuropeptide Y blocks and reverses interleukin-1β-induced anorexia in rats , 1996, Peptides.

[63]  A. Nath,et al.  Impairment by interleukin 1 beta and tumour necrosis factor alpha of the glucagon-induced increase in phosphoenolpyruvate carboxykinase gene expression and gluconeogenesis in cultured rat hepatocytes. , 1996, The Biochemical journal.

[64]  J. Roder,et al.  Physiological effects of CNTF-induced wasting. , 1996, Cytokine.

[65]  H. Ishitsuka,et al.  Murine interleukin‐12 prevents the development of cancer cachexia in a murine model , 1996, International journal of cancer.

[66]  F. López‐Soriano,et al.  The ubiquitin-dependent proteolytic pathway in skeletal muscle: its role in pathological states. , 1996, Trends in pharmacological sciences.

[67]  S. Willatts,et al.  Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. , 1996, Critical care medicine.

[68]  J. Friedman,et al.  Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. , 1996, The Journal of clinical investigation.

[69]  K. Fearon,et al.  Characterization of a cancer cachectic factor , 1996, Nature.

[70]  R. Henry,et al.  The expression of TNF alpha by human muscle. Relationship to insulin resistance. , 1996, The Journal of clinical investigation.

[71]  B. Spiegelman,et al.  IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-α- and Obesity-Induced Insulin Resistance , 1996, Science.

[72]  C. Plata-salamán Anorexia during acute and chronic disease. , 1996, Nutrition.

[73]  N. Agell,et al.  Muscle hypercatabolism during cancer cachexia is not reversed by the glucocorticoid receptor antagonist RU38486. , 1996, Cancer letters.

[74]  M. Croce,et al.  Identification of acute-phase proteins (APP) in circulating immune complexes (CIC) in esophageal cancer patients' sera. , 1996, Cancer investigation.

[75]  Y. le Maho,et al.  Stimulation of brown adipose tissue activity in tumor-bearing rats. , 1995, Canadian journal of physiology and pharmacology.

[76]  J. O'fallon,et al.  Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  L. Tessitore,et al.  Perturbations of triglycerides but not of cholesterol metabolism are prevented by anti-tumour necrosis factor treatment in rats bearing an ascites hepatoma (Yoshida AH-130). , 1995, British Journal of Cancer.

[78]  M. Muscaritoli,et al.  Tumor-induced changes in host metabolism: a possible marker of neoplastic disease. , 1995, Nutrition.

[79]  C. Garcı́a-Martı́nez,et al.  Interleukin-1 receptor antagonist (IL-1ra) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH-130). , 1995, Cancer letters.

[80]  K. Grabstein,et al.  Interleukin-15: a novel anabolic cytokine for skeletal muscle. , 1995, Endocrinology.

[81]  M. Miyata,et al.  Manifestations of cancer cachexia induced by colon 26 adenocarcinoma are not fully ascribable to interleukin‐6 , 1995, International journal of cancer.

[82]  H. Ishitsuka,et al.  Establishment and characterization of cachexia‐inducing and ‐non‐inducing clones of murine colon 26 carcinoma , 1995, International journal of cancer.

[83]  C. Garcı́a-Martı́nez,et al.  Enhanced leucine oxidation in rats bearing an ascites hepatoma (Yoshida AH-130) and its reversal by clenbuterol. , 1995, Cancer letters.

[84]  W. Rom,et al.  Thalidomide Treatment Reduces Tumor Necrosis Factor α Production and Enhances Weight Gain in Patients with Pulmonary Tuberculosis , 1995, Molecular medicine.

[85]  L. Tessitore,et al.  Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway. , 1995, The Journal of clinical investigation.

[86]  B. Spiegelman,et al.  Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.

[87]  N. Agell,et al.  Muscle wasting associated with cancer cachexia is linked to an important activation of the atp‐dependent ubiquitin‐mediated proteolysis , 1995, International journal of cancer.

[88]  E. Opara,et al.  Correlation between food intake and CSF IL-1 alpha in anorectic tumor bearing rats. , 1995, Neuroreport.

[89]  R. Wolfe,et al.  Insulin-like growth factor—I and insulin reduce leucine flux and oxidation in conscious tumor necrosis factor-indused dogs1 , 1995 .

[90]  K. Yasumoto,et al.  Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice. , 1995, Cancer research.

[91]  M. Burt,et al.  Interleukin-6 stimulates gluconeogenesis in primary cultures of rat hepatocytes. , 1995, Metabolism: clinical and experimental.

[92]  C. Garcı́a-Martı́nez,et al.  Alanine metabolism in rats bearing the Yoshida AH-130 ascites hepatoma. , 1994, Cancer letters.

[93]  M. Miyata,et al.  Characterization of Mice Bearing Subclones of Colon 26 Adenocarcinoma Disqualifies Interleukin‐6 as the Sole Inducer of Cachexia , 1994, Japanese journal of cancer research : Gann.

[94]  J. Blay,et al.  Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms. , 1994, Blood.

[95]  L. Tessitore,et al.  Anti-tumour necrosis factor-α treatment interferes with changes in lipid metabolism in a tumour cachexia model , 1994 .

[96]  J. Peters,et al.  Proteasomes: protein degradation machines of the cell. , 1994, Trends in biochemical sciences.

[97]  K. Feingold,et al.  Leukemia inhibitory factor induces changes in lipid metabolism in cultured adipocytes. , 1994, Endocrinology.

[98]  N. Agell,et al.  Ubiquitin Gene Expression in Skeletal Muscle Is Increased by Tumor Necrosis Factor-α , 1994 .

[99]  N. Agell,et al.  Ubiquitin gene expression is increased in skeletal muscle of tumour‐bearing rats , 1994, FEBS letters.

[100]  J. Gauldie,et al.  The acute phase response. , 1994, Immunology today.

[101]  C. Garcı́a-Martı́nez,et al.  Interleukin-6 does not activate protein breakdown in rat skeletal muscle. , 1994, Cancer letters.

[102]  J. Fischer,et al.  Possible role of neuropeptide Y in experimental cancer anorexia. , 1994, Advances in experimental medicine and biology.

[103]  J. Fischer,et al.  Hypothalamic concentration and release of neuropeptide Y into microdialysates is reduced in anorectic tumor-bearing rats. , 1994, Life sciences.

[104]  B. Spiegelman,et al.  Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. , 1994, Endocrinology.

[105]  C. Balázs,et al.  Immunological aspects of the effect of pentoxifylline (Trental) (a brief review). , 1994, Acta microbiologica et immunologica Hungarica.

[106]  L. Tessitore,et al.  Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. , 1993, The Journal of clinical investigation.

[107]  R. Nordan,et al.  Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. , 1993, The Journal of clinical investigation.

[108]  A. Cerami,et al.  Cachectin/TNF-mediated lactate production in cultured myocytes is linked to activation of a futile substrate cycle. , 1993, Cytokine.

[109]  M. Llovera,et al.  Effects of Tumor Necrosis Factor-α on Muscle-Protein Turnover in Female Wistar Rats , 1993 .

[110]  G. Kaplan,et al.  The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. , 1993, The Journal of infectious diseases.

[111]  N. Agell,et al.  Tumour necrosis factor‐α increases the ubiquitinization of rat skeletal muscle proteins , 1993 .

[112]  G. Kaplan,et al.  Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation , 1993, The Journal of experimental medicine.

[113]  B. Spiegelman,et al.  Through thick and thin: Wasting, obesity, and TNFα , 1993, Cell.

[114]  M. Llovera,et al.  Chronic tumour necrosis factor-alpha treatment modifies protein turnover in rat tissues. , 1993, Biochemistry and molecular biology international.

[115]  S. Endres,et al.  The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells. , 1993, International journal of immunopharmacology.

[116]  J. Bag,et al.  Expression of c‐jun/AP‐1 during myogenic differentiation in mouse C2C12 myoblasts , 1993, FEBS letters.

[117]  S. Mori,et al.  Leucine and manifestation of antitumor activity by valine-depleted amino acid imbalance. , 1993, Nutrition.

[118]  Nancy Y. Ip,et al.  The α component of the CNTF receptor is required for signaling and defines potential CNTF targets in the adult and during development , 1993, Neuron.

[119]  L. Tessitore,et al.  Humoral mediation for cachexia in tumour-bearing rats. , 1993, British Journal of Cancer.

[120]  B. Spiegelman,et al.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.

[121]  C. Garcı́a-Martı́nez,et al.  The role of cytokines in muscle wasting: Its relation with cancer cachexia , 1992, Medicinal research reviews.

[122]  L. Tessitore,et al.  Cholesterol metabolism during the growth of a rat ascites hepatoma (Yoshida AH-130). , 1992, British Journal of Cancer.

[123]  J. Tayek A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. , 1992, Journal of the American College of Nutrition.

[124]  T. Borg,et al.  Immunolocalization of ubiquitin conjugates at Z-bands and intercalated discs of rat cardiomyocytes in vitro and in vivo. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[125]  W. Yasmineh,et al.  Effect of Tumor Necrosis Factor on Enzymes of Gluconeogenesis in the Rat , 1992, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[126]  L. Tartaglia,et al.  Two TNF receptors. , 1992, Immunology today.

[127]  W. Fiers,et al.  Stimulation of lipolysis in cultured fat cells by tumor necrosis factor, interleukin-1, and the interferons is blocked by inhibition of prostaglandin synthesis. , 1992, Endocrinology.

[128]  C H Lang,et al.  Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. , 1992, Endocrinology.

[129]  K. Abe,et al.  Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor. , 1991, Cancer research.

[130]  P. Pani,et al.  Total and HDL cholesterol in human hematologic neoplasms. , 1991, International journal of hematology.

[131]  J. Stephens,et al.  Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. , 1991, The Journal of biological chemistry.

[132]  M. Tisdale,et al.  Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. , 1991, Cancer research.

[133]  C. Cangiano,et al.  Increased availability of tryptophan in brain as common pathogenic mechanism for anorexia associated with different diseases. , 1991, Nutrition.

[134]  M. Rechsteiner Natural substrates of the Ubiquitin proteolytic pathway , 1991, Cell.

[135]  A. Billiau,et al.  Severe cachexia in mice inoculated with interferon‐γ‐producing tumor cells , 1991 .

[136]  J. Fischer,et al.  Hyperammonemia and anorexia in Morris hepatoma-bearing rats , 1991, Physiology & Behavior.

[137]  G. Wilding,et al.  Transforming growth factor beta 1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice. , 1991, Cancer research.

[138]  W. Fiers,et al.  Interleukin 4 inhibits stimulation of hepatic lipogenesis by tumor necrosis factor, interleukin 1, and interleukin 6 but not by interferon-alpha. , 1991, Cancer research.

[139]  H. D. Mulligan,et al.  Lipogenesis in tumour and host tissues in mice bearing colonic adenocarcinomas. , 1991, British Journal of Cancer.

[140]  G. Kaplan,et al.  Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes , 1991, The Journal of experimental medicine.

[141]  F. López‐Soriano,et al.  The energy state of tumor-bearing rats. , 1991, The Journal of biological chemistry.

[142]  S. Lowry Cancer cachexia revisited: old problems and new perspectives. , 1991, European journal of cancer.

[143]  D. Gandara,et al.  Progress in the control of acute and delayed emesis induced by cisplatin. , 1991, European journal of cancer.

[144]  K. Lundholm,et al.  Elevated energy expenditure in cancer patients with solid tumours. , 1991, European journal of cancer.

[145]  G. Opdenakker,et al.  Anti-interferon-gamma antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia. , 1991, European journal of cancer.

[146]  R. Krauss,et al.  Tumor necrosis factor acutely increases plasma levels of very low density lipoproteins of normal size and composition. , 1990, Endocrinology.

[147]  W. Fiers,et al.  Search for mediators of the lipogenic effects of tumor necrosis factor: potential role for interleukin 6. , 1990, Cancer research.

[148]  W. Mcbride,et al.  Prevalence and clinical characteristics of a high cardiac output state in patients with multiple myeloma. , 1990, The American journal of medicine.

[149]  F. López‐Soriano,et al.  The oxidation of leucine in tumour-bearing rats. , 1990, The Biochemical journal.

[150]  H. Ishitsuka,et al.  Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. , 1990, Cancer research.

[151]  J. Patton,et al.  Recombinant Tumor Necrosis Factor-α Chronically Administered in Rats: Lack of Cachectic Effect , 1990 .

[152]  L. Giacomelli,et al.  Plasma clearance of exogenous lipids in patients with malignant disease. , 1990, Nutrition.

[153]  M. McNurlan,et al.  Increased protein turnover despite normal energy metabolism and responses to feeding in patients with lung cancer. , 1990, Cancer research.

[154]  M. Siimes,et al.  Tumor necrosis factor in children with malignancies. , 1990, Cancer research.

[155]  M. Buse,et al.  Administration of endotoxin, tumor necrosis factor, or interleukin 1 to rats activates skeletal muscle branched-chain alpha-keto acid dehydrogenase. , 1990, The Journal of clinical investigation.

[156]  S. Fried,et al.  Cachectin/tumor necrosis factor decreases human adipose tissue lipoprotein lipase mRNA levels, synthesis, and activity. , 1989, Journal of lipid research.

[157]  N. Rothwell,et al.  Increased brown adipose tissue activity in children with malignant disease. , 1989, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[158]  M. Tisdale,et al.  Nitrogen excretion in cancer cachexia and its modification by a high fat diet in mice. , 1989, Cancer research.

[159]  M. Serio,et al.  Multiple cytokines stimulate hepatic lipid synthesis in vivo. , 1989, Endocrinology.

[160]  K. Yamaguchi,et al.  Purification of a lipoprotein lipase-inhibiting protein produced by a melanoma cell line associated with cancer cachexia. , 1989, Biochemical and biophysical research communications.

[161]  M. Serio,et al.  Tumor necrosis factor stimulates hepatic lipid synthesis and secretion. , 1989, Endocrinology.

[162]  J. Pomposelli,et al.  Infusion of tumor necrosis factor/cachectin promotes muscle catabolism in the rat. A synergistic effect with interleukin 1. , 1989, The Journal of clinical investigation.

[163]  D. Brenner,et al.  Prolonged activation of jun and collagenase genes by tumour necrosis factor-α , 1989, Nature.

[164]  J. Norton,et al.  Cachectin activity in the serum of cachectic, tumor-bearing rats. , 1989, Archives of surgery.

[165]  D. Williamson,et al.  Tumour necrosis factor alpha (cachectin) mimics some of the effects of tumour growth on the disposal of a [14C]lipid load in virgin, lactating and litter-removed rats. , 1988, The Biochemical journal.

[166]  L. Moldawer,et al.  Monocytic production and plasma bioactivities of interleukin‐1 and tumour necrosis factor in human cancer , 1988, European journal of clinical investigation.

[167]  S. Mahony,et al.  Induction of weight loss and metabolic alterations by human recombinant tumour necrosis factor. , 1988, British Journal of Cancer.

[168]  J. Norton,et al.  Cachectin/tumor necrosis factor: a possible mediator of cancer anorexia in the rat. , 1988, Cancer research.

[169]  P. Kern Recombinant human tumor necrosis factor does not inhibit lipoprotein lipase in primary cultures of isolated human adipocytes. , 1988, Journal of lipid research.

[170]  J. Kuhn,et al.  Tumor necrosis factor not detectable in patients with clinical cancer cachexia. , 1988, Journal of the National Cancer Institute.

[171]  A. Cerami,et al.  Detection of circulating tumor necrosis factor after endotoxin administration. , 1988, The New England journal of medicine.

[172]  S. H. Socher,et al.  Recombinant human tumor necrosis factor induces acute reductions in food intake and body weight in mice , 1988, The Journal of experimental medicine.

[173]  D. Williamson,et al.  Tissue-specific effects of rapid tumour growth on lipid metabolism in the rat during lactation and on litter removal. , 1988, The Biochemical journal.

[174]  K. Kim,et al.  Effect of tumor necrosis factor on acetyl-coenzyme A carboxylase gene expression and preadipocyte differentiation. , 1988, Molecular endocrinology.

[175]  K. Tracey,et al.  Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation , 1988, The Journal of experimental medicine.

[176]  P. Selby,et al.  ENDOGENOUS TUMOUR NECROSIS FACTOR IN CANCER PATIENTS , 1988, The Lancet.

[177]  B. Aggarwal,et al.  Characterization of the in vitro and in vivo species preference of human and murine tumor necrosis factor-alpha. , 1988, Cancer research.

[178]  S. Enerbäck,et al.  Regulation of lipoprotein lipase mRNA content in 3T3-L1 cells by tumour necrosis factor. , 1988, The Biochemical journal.

[179]  Kevin J. Tracey,et al.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.

[180]  J. Gabrilove,et al.  The acute metabolic effects of tumor necrosis factor administration in humans. , 1987, Archives of surgery.

[181]  J. Tavernier,et al.  EVIDENCE FOR TUMOUR NECROSIS FACTOR/CACHECTIN PRODUCTION IN CANCER , 1987, The Lancet.

[182]  J. Norton,et al.  Gluconeogenesis in the tumor-influenced rat hepatocyte: importance of tumor burden, lactate, insulin, and glucagon. , 1987, Journal of the National Cancer Institute.

[183]  R. Warren,et al.  Protein synthesis in hepatocytes isolated from patients with gastrointestinal malignancy. , 1987, The Journal of clinical investigation.

[184]  F. López‐Soriano,et al.  Blood amino acid compartmentation in mice bearing Lewis lung carcinoma. , 1987, Cancer research.

[185]  L. F. Fajardo,et al.  Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. , 1987, Science.

[186]  J. Norton,et al.  Impact of insulin on doxorubicin-induced rat host toxicity and tumor regression. , 1987, Cancer research.

[187]  A. Oliff,et al.  Tumors secreting human TNF/cachectin induce cachexia in mice , 1987, Cell.

[188]  L. Moldawer,et al.  Interleukin 1, tumour necrosis factor-alpha (cachectin) and the pathogenesis of cancer cachexia. , 1987, Clinical physiology.

[189]  J. Norton,et al.  Preoperative insulin reverses cachexia and decreases mortality in tumor-bearing rats. , 1987, The Journal of surgical research.

[190]  K. Feingold,et al.  Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo. , 1987, The Journal of clinical investigation.

[191]  J. Tavernier,et al.  Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. , 1987, The Journal of biological chemistry.

[192]  B. Camitta,et al.  Close association of accelerated rates of whole body protein turnover (synthesis and breakdown) and energy expenditure in children with newly diagnosed acute lymphocytic leukemia. , 1987, JPEN. Journal of parenteral and enteral nutrition.

[193]  M. Kawakami,et al.  Human recombinant TNF suppresses lipoprotein lipase activity and stimulates lipolysis in 3T3-L1 cells. , 1987, Journal of biochemistry.

[194]  L. Tessitore,et al.  Early development of protein metabolic perturbations in the liver and skeletal muscle of tumour-bearing rats. A model system for cancer cachexia. , 1987, The Biochemical journal.

[195]  P. Pekala,et al.  Regulation of lipoprotein lipase synthesis and 3T3-L1 adipocyte metabolism by recombinant interleukin 1. , 1986, Biochimica et biophysica acta.

[196]  P. Scuderi,et al.  RAISED SERUM LEVELS OF TUMOUR NECROSIS FACTOR IN PARASITIC INFECTIONS , 1986, The Lancet.

[197]  A. Waage,et al.  Detection of Tumour Necrosis Factor‐Like Cytotoxicity in Serum from Patients With Septicaemia but Not from Untreated Cancer Patients , 1986, Scandinavian journal of immunology.

[198]  P. Pekala,et al.  Regulation of lipoprotein lipase synthesis by recombinant tumor necrosis factor--the primary regulatory role of the hormone in 3T3-L1 adipocytes. , 1986, Archives of biochemistry and biophysics.

[199]  B. Aggarwal,et al.  Interferons and tumor necrosis factors have similar catabolic effects on 3T3 L1 cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[200]  R. Bergman,et al.  Pathophysiology of malnutrition in the adult cancer patient , 1986, Cancer.

[201]  N. Rothwell,et al.  Brown adipose tissue and the response to overfeeding. , 1986, Biochemical Society transactions.

[202]  B. Beutler,et al.  Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3-L1 cells. , 1985, Journal of immunology.

[203]  W. Dewys Management of cancer cachexia. , 1985, Seminars in oncology.

[204]  H. Holtmann,et al.  CACHECTIN/TUMOUR-NECROSIS-FACTOR PRODUCTION BY CANCER PATIENTS , 1985, The Lancet.

[205]  A. Varshavsky,et al.  The ubiquitin system: functions and mechanisms , 1985 .

[206]  B. Beutler,et al.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. , 1985, Science.

[207]  P. Lazo Tumour‐host metabolic interaction and cachexia , 1985, FEBS letters.

[208]  R. Makuch,et al.  Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer. , 1985, Cancer research.

[209]  C. Hardy,et al.  Cancer and malnutrition—A critical interaction: A review , 1985, American journal of hematology.

[210]  S. Eisenberg,et al.  High density lipoprotein metabolism. , 1984, Journal of lipid research.

[211]  W. Mitch,et al.  Specificity of the effects of leucine and its metabolites on protein degradation in skeletal muscle. , 1984, The Biochemical journal.

[212]  M. Skinner,et al.  Acute‐Phase Proteins or Tumour Markers: The Role of SAA, SAP, CRP and CEA as Indicators of Metastasis in a Broad Spectrum of Neoplastic Diseases , 1984, Scandinavian journal of immunology.

[213]  P. Garlick,et al.  Protein synthesis in liver and skeletal muscle of mice bearing an ascites tumor. , 1984, Cancer research.

[214]  A. Ciechanover,et al.  The ubiquitin‐mediated proteolytic pathway and mechanisms of energy‐dependent intracellular protein degradation , 1984, Journal of cellular biochemistry.

[215]  D. J. Millward,et al.  Depressed protein synthesis is the dominant characteristic of muscle wasting and cachexia. , 1983, Clinical physiology.

[216]  A. Cerami,et al.  Selective inhibition of synthesis of enzymes for de novo fatty acid biosynthesis by an endotoxin-induced mediator from exudate cells. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[217]  D. Nicholls The thermogenic mechanism of brown adipose tissue , 1983, Bioscience reports.

[218]  M. Rennie,et al.  Efflux of 3-methylhistidine from the leg in cancer patients who experience weight loss. , 1982, Cancer research.

[219]  G. Keusch,et al.  Infection and diabetes: the case for glucose control. , 1982, The American journal of medicine.

[220]  A. Goldberg,et al.  Does leucine, leucyl-tRNA, or some metabolite of leucine regulate protein synthesis and degradation in skeletal and cardiac muscle? , 1982, The Journal of biological chemistry.

[221]  A. Richmond,et al.  Metabolic approaches to cancer cachexia. , 1982, Annual review of nutrition.

[222]  M. Tee,et al.  Leucine oxidation and protein degradation in the extensor digitorum longus and soleus of the tumor-bearing host. , 1981, Biochemical medicine.

[223]  M. Brennan Total parenteral nutrition in the cancer patient. , 1981, The New England journal of medicine.

[224]  J. Mead,et al.  Characterization of a lipid mobilizing factor from tumors. , 1981, Progress in lipid research.

[225]  H. Okuda,et al.  Purification and characterization of a lipolytic factor (toxohormone-L) from cell-free fluid of ascites sarcoma 180. , 1981, Cancer research.

[226]  M. Kutner,et al.  Protein-calorie undernutrition in hospitalized cancer patients. , 1980, The American journal of medicine.

[227]  A Ciechanover,et al.  Proposed role of ATP in protein breakdown: conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[228]  A. Reilley,et al.  An investigation of the cause of death from cancer , 1980, Journal of surgical oncology.

[229]  T. Scherstén,et al.  Protein synthesis in liver tissue under the influence of a methylcholanthrene-induced sarcoma in mice. , 1979, Cancer research.

[230]  J. Keilson,et al.  Gluconeogenesis from alanine in patients with progressive malignant disease. , 1979, Cancer research.

[231]  W. Dewys Anorexia as a general effect of cancer , 1979, Cancer.

[232]  R. Adams,et al.  Principles of Neurology , 1996 .

[233]  J. D. Davis,et al.  A model for the control of ingestion. , 1977, Psychological review.

[234]  E. Racker Why do tumor cells have a high aerobic glycolysis? , 1976, Journal of cellular physiology.

[235]  S. Adibi Metabolism of branched-chain amino acids in altered nutrition. , 1976, Metabolism: clinical and experimental.

[236]  E. Copeland,et al.  Effect of Intravenous Hyperalimentation on Established Delayed Hypersensitivity in the Cancer Patient , 1976, Annals of surgery.

[237]  M. Buse,et al.  Leucine. A possible regulator of protein turnover in muscle. , 1975, The Journal of clinical investigation.

[238]  A. Goldberg,et al.  Effects of insulin, glucose, and amino acids on protein turnover in rat diaphragm. , 1975, The Journal of biological chemistry.

[239]  R. Albertini,et al.  Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. , 1968, Lancet.

[240]  J. MacGee,et al.  ALTERED CORTISOL METABOLISM IN ADVANCED CANCER AND OTHER TERMINAL ILLNESSES: EXCRETION OF 6-HYDROXYCORTISOL. , 1964, Metabolism: clinical and experimental.

[241]  Foss Mv CARDIAC ARREST AND ADRENALINE. , 1964 .

[242]  J. Holland,et al.  Effects of Krebs-2 carcinoma on the lipide metabolism of male Swiss mice. , 1962, Cancer research.

[243]  A. Glicksman,et al.  Diabetes and altered carbohydrate metabolism in patients with cancer , 1956, Cancer.

[244]  R. J. Block,et al.  Amino acid handbook , 1956 .

[245]  S. Warren THE IMMEDIATE CAUSES OF DEATH IN CANCER , 1932 .